Oligodendroglioma
Symptoms, Doctors, Treatments, Advances & More

Learn About Oligodendroglioma

View Main Condition: Brain Tumor

What is the definition of Oligodendroglioma?
Oligodendroglioma is a type of brain tumor that develops from oligodendrocytes, which are specialized cells that protect neurons (nerve cells). Oligodendroglioma can occur in the brain and spinal cord.  Oligodendrogliomas are also classified as either Grade 2 or Grade 3. Grade 2 oligodendrogliomas do not spread as aggressively as Grade 3 and are less likely to cause severe symptoms. 
What are the causes of Oligodendroglioma?
The cause of oligodendrogliomas is still unknown. However, oligodendrogliomas generally tend to be more common in adults than children. Men are also more likely to develop oligodendrogliomas than women.
What are the symptoms of Oligodendroglioma?
Symptoms for oligodendroglioma primarily depend on the size and location of the tumor. Common symptoms include seizures, headaches, short-term memory issues, personality changes, and weakness on one side of the body.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Oligodendroglioma?
Treatment for oligodendroglioma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove the tumor is generally the first step in treating oligodendroglioma. Depending on the tumor's location, surgery may be able to entirely remove smaller oligodendrogliomas. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of oligodendrogliomas. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.
Who are the top Oligodendroglioma Local Doctors?
Patrick Y. Wen
Elite in Oligodendroglioma
Elite in Oligodendroglioma

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
Languages Spoken:
English
Offers Telehealth

Patrick Wen is a Neurologist in Boston, Massachusetts. Dr. Wen is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Matthias Holdhoff
Elite in Oligodendroglioma
Elite in Oligodendroglioma

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
Languages Spoken:
English, German
Offers Telehealth

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

 
 
 
 
Learn about our expert tiers
Learn More
Chetan Bettegowda
Elite in Oligodendroglioma
Elite in Oligodendroglioma

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville

10753 Falls Road, Pavilion II, Suite 115, Pavilion II, Suite 115, 
Lutherville, MD 
Languages Spoken:
English, Kannada
Offers Telehealth

Chetan Bettegowda is the director of the Johns Hopkins Department of Neurosurgery. He offers comprehensive treatments for adult patients with benign and malignant brain tumors, specializing in the treatment of patients with primary brain tumors such as gliomas, meningiomas and pituitary tumors. He performs both open surgery and stereotactic radiosurgery for patients with metastatic tumors to the brain, and also provides stereotactic radiosurgery for other neurological disorders, including spinal tumors, trigeminal neuralgia and skull-base tumors. Dr. Bettegowda is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Trigeminal Neuralgia, Astrocytoma, Glioblastoma, Rhizotomy, and Microvascular Decompression.

What is the outlook (prognosis) for Oligodendroglioma?
The prognosis for oligodendroglioma is very good with current treatments. When the tumor can be removed, survival rates are over 90%. If the tumor can not be removed but radiation therapy is used, survival rates are between 80-90%.
How do I prevent Oligodendroglioma?
There is no known way to prevent oligodendrogliomas. However, if you develop any symptoms common to oligodendroglioma, it is recommended to make an appointment with your doctor to be properly diagnosed.
What are the latest Oligodendroglioma Clinical Trials?
A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

Summary: This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or G...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade 2 or 3 Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial

Summary: Oligodendrogliomas in the novel edition of the Central Nervous System (CNS) World Health Organization (WHO) classification are now molecularly defined by isocitrate dehydrogenase (IDH)1 or IDH2 mutations and 1p/19q co-deletion. The prognosis of these molecularly defined tumors is to be determined in new series since survival data from older histology-based studies and population-based registries a...

What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.